Cetera Investment Advisers Acquires 444 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Cetera Investment Advisers increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,536 shares of the specialty pharmaceutical company’s stock after buying an additional 444 shares during the period. Cetera Investment Advisers’ holdings in Jazz Pharmaceuticals were worth $1,308,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Burney Co. raised its stake in shares of Jazz Pharmaceuticals by 7.0% during the first quarter. Burney Co. now owns 25,512 shares of the specialty pharmaceutical company’s stock worth $3,167,000 after buying an additional 1,672 shares during the last quarter. Convergence Investment Partners LLC grew its holdings in Jazz Pharmaceuticals by 24.4% during the first quarter. Convergence Investment Partners LLC now owns 10,428 shares of the specialty pharmaceutical company’s stock valued at $1,295,000 after purchasing an additional 2,043 shares during the period. Readystate Asset Management LP grew its holdings in Jazz Pharmaceuticals by 7.7% during the first quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 1,635 shares during the period. KLP Kapitalforvaltning AS grew its holdings in Jazz Pharmaceuticals by 1.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock valued at $2,148,000 after purchasing an additional 300 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Jazz Pharmaceuticals during the first quarter valued at approximately $10,900,000. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAZZ. Wall Street Zen cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Piper Sandler restated an “overweight” rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada decreased their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.43.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $111.30 on Monday. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The firm has a fifty day simple moving average of $111.27 and a 200 day simple moving average of $117.47. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of -16.54, a PEG ratio of 5.15 and a beta of 0.34. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the company posted $5.30 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. Research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.